Can a virtual team of researchers break a 40-year logjam in this rare cancer?
John Carroll
August 25, 2025
When Mac Tichenor’s son Willie died of osteosarcoma at the age of 19 back in 2006, oncologists still relied on a decades-old chemo regimen called MAP — high-dose methotrexate, combined with doxorubicin and cisplatin. Typically, for young patients with the rare bone cancer, it staved off death for a while.
UPDATES AND NEWS
Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working | The New York Times
We can prevent ovarian cancer. Women deserve the option. | USA Today
Fallopian tube removal may lower ovarian cancer risk | Good Morning America
The Lustgarten Foundation and Break Through Cancer Announce New Clinical Trial Evaluating KRAS-targeted Immunotherapy Strategy for Pancreatic Cancer
BE PART OF THE MISSION
Stay Informed, Make an Impact
Subscribe
Be the first to hear about cutting-edge research, pioneering projects, and the latest advancements in Break Through Cancer science. Sign up to stay informed.
Give
Your contribution fuels groundbreaking research in some of the most challenging cancers. Every gift accelerates progress. For more information please contact Michaela Forand at MF@breakthroughcancer.org or 1-800-757-9881 ext 2.
